In agreement with the murine models, both alisertib and panobinostat could reduce patient-derived CLL cell chemotaxis towards CXCL12 significantly (Fig. 6E), with the combination treatment showing additive effects. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.